Analysis of interleukin (IL)-1β IL-1 receptor antagonist, soluble IL-1 receptor type II and IL-1 accessory protein in HCV-associated lymphoproliferative disorders
Massimo Libra(University of Catania), Ferdinando Nicoletti(University of Catania), Marco Donia(University of Copenhagen), Anna Linda Zignego(University of Florence), María Clorinda Mazzarino(University of Catania), Katia Mangano(University of Catania), Massimiliano Anzaldi(University of Catania), Guido Scalia(University of Catania), Cinzia Quattrocchi, Salvatore Santo Signorelli(University of Catania), Roberto Di Marco(University of Catania), Vallì De Re(Centro di Riferimento Oncologico)
Cited by 21
Related Papers
Natural products in drug discovery: advances and opportunities
|Nature Reviews Drug Discovery|2021|5.2k
Evolution of Cancer Pharmacological Treatments at the Turn of the Third Millennium
|Frontiers in Pharmacology|2018|878
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Inhibitors: Rationale and Importance to Inhibiting These Pathways in Human Health
|Oncotarget|2011|579
GSK-3 as potential target for therapeutic intervention in cancer
|Oncotarget|2014|508